FDA Restricts Use Of Sanofi-Aventis Drug

Law360, New York (February 13, 2007, 12:00 AM EST) -- On the eve of a congressional hearing over drug safety, the U.S. Food and Drug Administration revealed label and usage changes for antibiotic Ketek.

The FDA said Monday that Sanofi-Aventis could no longer market Ketek for acute bacterial sinusitis and acute bacterial exacerbations of chronic bronchitis. “The agency has determined that the balance of benefits and risks no longer support approval of the drug for these indications,” it said.

Ketek will remain on the market for community-acquired pneumonia. But the product labeling now carries a boxed...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.